Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker. 
Advertisement

Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
US Initiative To End HIV Epidemic Will Boost PrEP Access
Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear
Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
ViiV Steals A March On Gilead with HIV Doublet Data
Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana
Portola Finally Gets FDA OK For Factor Xa Antidote AndexXa
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel